Trial reportBlood2017
Mutational landscape and response are conserved in peripheral blood of AML and MDS patients during decitabine therapy.
Abstract readClinical TrialLetter
In one paragraph
Trial report in Blood, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Breaking the Bone Marrow Barrier: Peripheral Blood as a Gateway to Measurable Residual Disease Detection in Acute Myelogenous Leukemia.American journal of hematology · 2025Review
- Monitoring clonal burden as an alternative to blast count for myelodysplastic neoplasm treatment response.Leukemia · 2025Article
- Correlation between peripheral blood and bone marrow mutations among patients with MDS from the National MDS Study.Blood neoplasia · 2024Article
- Molecular responses in decitabine- and decitabine/ venetoclax-treated patients with acute myeloid leukemia and myelodysplastic syndromes.Haematologica · 2024Article
- Low expression of miR-182 caused by DNA hypermethylation accelerates acute lymphocyte leukemia development by targeting PBX3 and BCL2: miR-182 promoter methylation is a predictive marker for hypomethylation agents + BCL2 inhibitor venetoclax.Clinical epigenetics · 2024Article
- How to classify risk based on clinical and molecular modeling: integrating molecular markers in the risk assessment of myelodysplastic syndrome.Hematology. American Society of Hematology. Education Program · 2023Article
- Moving toward a conceptualization of measurable residual disease in myelodysplastic syndromes.Blood advances · 2023Article
- Clonal dynamics using droplet digital polymerase chain reaction in peripheral blood predicts treatment responses in myelodysplastic syndrome.Haematologica · 2023Article
- Article
- Polyclonal evolution of Fanconi anemia to MDS and AML revealed at single cell resolution.Experimental hematology & oncology · 2022Article
- Functional Classification ofCancers · 2020Article
- Spanish Guidelines for the use of targeted deep sequencing in myelodysplastic syndromes and chronic myelomonocytic leukaemia.British journal of haematology · 2020Article
- Sequencing-Based Measurable Residual Disease Testing in Acute Myeloid Leukemia.Frontiers in cell and developmental biology · 2020Review
- MRD evaluation of AML in clinical practice: are we there yet?Hematology. American Society of Hematology. Education Program · 2019Review
- Acute myeloid leukemia-induced T-cell suppression can be reversed by inhibition of the MAPK pathway.Blood advances · 2019Article
- Clinical implications of subclonalHaematologica · 2019Article
- When to obtain genomic data in acute myeloid leukemia (AML) and which mutations matter.Hematology. American Society of Hematology. Education Program · 2018Review
- Treatments targeting MDS genetics: a fool's errand?Hematology. American Society of Hematology. Education Program · 2018Review
- When to obtain genomic data in acute myeloid leukemia (AML) and which mutations matter.Blood advances · 2018Review
- Depletion of ZBTB38 potentiates the effects of DNA demethylating agents in cancer cells via CDKN1C mRNA up-regulation.Oncogenesis · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Eric J DuncavageDepartment of Pathology and Immunology.
Geoffrey L UyDivision of Oncology, Department of Internal Medicine.
Allegra A PettiMcDonnell Genome Institute, and.
Christopher A MillerDivision of Oncology, Department of Internal Medicine.
Yi-Shan LeeDepartment of Pathology and Immunology.
Bevan TandonDepartment of Pathology and Immunology.
Feng GaoDivision of Public Health Sciences, Department of Surgery, Washington University, St. Louis, MO.
Catrina C FronickMcDonnell Genome Institute, and.
Michelle O'LaughlinMcDonnell Genome Institute, and.
Robert S FultonMcDonnell Genome Institute, and.
Richard K WilsonMcDonnell Genome Institute, and.
Meagan A JacobyDivision of Oncology, Department of Internal Medicine.
Amanda F CashenDivision of Oncology, Department of Internal Medicine.
Lukas D WartmanDivision of Oncology, Department of Internal Medicine.
Matthew J WalterDivision of Oncology, Department of Internal Medicine.
Peter WesterveltDivision of Oncology, Department of Internal Medicine.
Daniel C LinkDivision of Oncology, Department of Internal Medicine.
John F DiPersioDivision of Oncology, Department of Internal Medicine.
Timothy J LeyDivision of Oncology, Department of Internal Medicine.
John S WelchDivision of Oncology, Department of Internal Medicine.
Funding
Washington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI TIMOTHY J. EBERLEIN · 2001 to 2026
$128.0MSpecimen Acquistition and Expression ProfilingP01CA101937 · NCI · WASHINGTON UNIVERSITY · PI LEY, TIMOTHY J. · 2003 to 2023
$58.8MTargeting the Bone Marrow Microenvironment In Acute Lymphocytic LeukemiaP50CA171963 · NCI · WASHINGTON UNIVERSITY · PI TODD A FEHNIGER · 2013 to 2026
$31.6MMolecular Pathogenesis of Acute Myeloid LeukemiaR35CA197561 · NCI · WASHINGTON UNIVERSITY · PI Timothy J. Ley · 2015 to 2026
$11.0MRETINOIDS IN HEMATOPOIESISR01HL128447 · NHLBI · WASHINGTON UNIVERSITY · PI WELCH, JOHN S · 2016 to 2020
$1.9MHISTONE H3 METHYLATION AND EPIGENOMICS IN ACUTE LEUKEMIAK08CA166229 · NCI · WASHINGTON UNIVERSITY · PI WARTMAN, LUKAS D · 2013 to 2017
$768kNCI NIH HHS K08 CA166229NCI NIH HHS P01 CA101937NCI NIH HHS P30 CA091842NCI NIH HHS P50 CA171963NCI NIH HHS R35 CA197561NHLBI NIH HHS R01 HL128447
Abstract
PubMed holds no abstract for this paper.
Indexed as
Blood CellsLeukemia, Myeloid, AcuteMutationMyelodysplastic SyndromesNeoplasm ProteinsAzacitidineDecitabineFemaleHumansMaleAzacitidineDecitabineNeoplasm Proteins
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.